AlphaMark Advisors LLC Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

AlphaMark Advisors LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,740 shares of the medical research company’s stock after buying an additional 201 shares during the quarter. AlphaMark Advisors LLC’s holdings in Edwards Lifesciences were worth $1,313,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of EW. EverSource Wealth Advisors LLC grew its position in Edwards Lifesciences by 42.9% during the second quarter. EverSource Wealth Advisors LLC now owns 932 shares of the medical research company’s stock worth $86,000 after buying an additional 280 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Edwards Lifesciences by 73.6% during the second quarter. Public Sector Pension Investment Board now owns 23,267 shares of the medical research company’s stock worth $2,149,000 after purchasing an additional 9,863 shares in the last quarter. APG Asset Management N.V. increased its position in shares of Edwards Lifesciences by 2.9% in the second quarter. APG Asset Management N.V. now owns 492,537 shares of the medical research company’s stock worth $42,450,000 after purchasing an additional 13,832 shares during the last quarter. Daymark Wealth Partners LLC raised its stake in Edwards Lifesciences by 8.3% in the second quarter. Daymark Wealth Partners LLC now owns 8,533 shares of the medical research company’s stock valued at $788,000 after purchasing an additional 656 shares in the last quarter. Finally, MBB Public Markets I LLC bought a new stake in Edwards Lifesciences during the second quarter valued at approximately $4,055,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

EW stock opened at $68.98 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a 50-day moving average of $72.33 and a 200 day moving average of $70.68. The company has a market cap of $40.68 billion, a P/E ratio of 9.95, a PEG ratio of 3.54 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analyst Ratings Changes

EW has been the topic of several research reports. Truist Financial restated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a research note on Thursday, January 16th. Stifel Nicolaus increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average target price of $78.48.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,000 shares of company stock valued at $2,195,180. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.